The recent impressive clinical responses to antibody-based immunotherapy have prompted
the identification of clinically relevant tumor antigens that can serve as targets in solid …

Immunotherapy for cancer is a rapidly developing treatment that modifies the immune
system and enhances the antitumor immune response. B7-H3 (CD276), a member of the B7 …

Identifying the mechanisms underlying the regulation of immune checkpoint molecules and
the therapeutic impact of targeting them in cancer is critical. Here we show that high …

Abstract B7-H3 (CD276) is an important immune checkpoint member of the B7 and CD28
families. Induced on antigen-presenting cells, B7-H3 plays an important role in the inhibition …

The first generation of immune checkpoint inhibitors (anti-CTLA-4 and anti-PD-1/PD-L1)
targeted natural immune homeostasis pathways, co-opted by cancers, to drive anti-tumor …

Most patients with triple negative breast cancer (TNBC) do not respond to anti-PD1/PDL1
immunotherapy, indicating the necessity to explore immune checkpoint targets. B7H3 is a …

The immune system is guided by a series of checks and balances, a major component of
which is a large array of co-stimulatory and co-inhibitory pathways that modulate the host …

Glioblastoma (GBM) remains one of the most malignant primary tumors in adults, with a 5-
year survival rate less than 10% because of lacking effective treatment. Here, we aimed to …

Checkpoint immunotherapy has yielded meaningful responses across many cancers but
has shown modest efficacy in advanced prostate cancer. B7 homolog 3 protein (B7 …

Background: B7-H3 (CD276), part of the B7 superfamily of immune checkpoint molecules,
has been shown to have an immunomodulatory role. Its regulation, receptor and mechanism …